** Brokerage Raymond James resumes coverage on drugmaker BridgeBio Pharma BBIO.O with "outperform" rating; sets PT at $57, a 66.4% upside to the stock's last close
** Brokerage anticipates BBIO's launch of heart disease drug Attruby to be faster than expected, even with a significant discount on revenues after 2028 due to potential pricing pressure from the loss of exclusivity for Pfizer's PFE.N tafamidis
** "We expect it to gain meaningful market share in the newly diagnosed population," brokerage adds
** BBIO can leverage its drugs Encaleret and BBP-418 to form partnerships and improve finances — brokerage
** 14 out of 16 brokerages rate the stock "buy" or higher, 2 rate it "hold", per data compiled by LSEG
** Stock has fallen 4.1% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。